Bristol-Myers Squibb Company
Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors

Abstract:

The disclosure relates to compounds of formula I: Formula I which inhibit .alpha..sub.V-containing integrins, and includes pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of .alpha.V-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders. ##STR00001##